Plain-English translation of NCT07828704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a small pilot study testing whether 5-ALA (Gleolan), a medication already approved for brain surgery, can also help surgeons see kidney tumors more clearly. You would take the medication by mouth a few hours before your scheduled kidney tumor surgery, and the surgeon would use special blue light during the operation to see if the tumor glows, making it easier to remove completely while protecting healthy kidney tissue.
During kidney cancer surgery, it can be difficult for surgeons to tell exactly where the tumor ends and healthy kidney begins. This trial is exploring whether the medication can light up tumors under blue light, giving surgeons a better view and potentially improving surgery outcomes.
You likely qualify if…
You likely don't qualify if…
You would have baseline blood tests to make sure you're healthy enough for surgery. On the day of your operation, you'll take the medication by mouth 2–4 hours before the procedure. During surgery, the surgeon will use a special blue light endoscope to look for glowing tumors and help guide the removal. You'll be monitored during the surgery for any side effects and followed afterward as part of standard care.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States